Upon joining the study, the patient will be randomly assigned to receive either the medication BI 1819479 or a placebo. The placebo is a tablet that looks identical to the medication but does not contain the active substance.

The study is designed to be double-blind, meaning neither the patient nor the researchers will know which treatment the patient is receiving.

The patient will take the assigned tablet orally. The specific dosage and frequency will be determined by the study protocol, which aims to evaluate different doses of BI 1819479.

The treatment period will last for at least 24 weeks, with the possibility of extending up to a maximum of 52 weeks.

Throughout the study, the patient’s lung function will be regularly monitored. This includes measuring the Forced Vital Capacity (FVC), which is the amount of air the patient can forcibly exhale from the lungs after taking the deepest breath possible.

The primary goal is to assess the annual rate of decline in FVC over the treatment period.

At the end of the treatment period, the patient will undergo a final evaluation to measure any changes in lung function, specifically the absolute change in FVC from the baseline at Week 24.

The results will help determine the effectiveness and safety of BI 1819479 in treating idiopathic pulmonary fibrosis.